[Form 4] Oric Pharmaceuticals, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Insider Trading Alert: Angie You, Director at Oric Pharmaceuticals (ORIC), has made significant stock purchases over two consecutive days in June 2025:

• June 20, 2025: Acquired 26,597 shares at weighted average price of $9.3871 per share
• June 23, 2025: Purchased additional 1,403 shares at $9.43 per share

Total position following these transactions: 28,000 shares held directly. The first purchase was executed across multiple price points ranging from $9.14 to $9.50. These direct market purchases by a director signal potential confidence in the company's prospects. The transactions were reported via Form 4 filing and executed through an attorney-in-fact, Christian Kuhlen.

Positive

• Director Angie You made significant open market purchases totaling 28,000 shares worth approximately $263,000, demonstrating insider confidence in the company's prospects

Negative

• None.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

You Angie

(Last) (First) (Middle)

C/O ORIC PHARMACEUTICALS, INC.

240 E. GRAND AVE., 2ND FLOOR

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Oric Pharmaceuticals, Inc. [ ORIC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/20/2025		P		26,597	A	$9.3871(1)	26,597	D
Common Stock	06/23/2025		P		1,403	A	$9.43	28,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the weighted average share price of an aggregate total of 26,597 shares purchased in the price range of $9.14 to $9.50 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

	/s/ Christian Kuhlen, attorney-in-fact	06/23/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many shares of ORIC Pharmaceuticals (ORIC) did Director Angie You purchase on June 20, 2025?

Director Angie You purchased 26,597 shares of ORIC common stock on June 20, 2025 at a weighted average price of $9.3871 per share.

What was the total investment amount in ORIC stock by Director Angie You in June 2025?

Director Angie You invested approximately $262,000 in total, purchasing 26,597 shares at $9.3871 per share on June 20 and an additional 1,403 shares at $9.43 per share on June 23, 2025.

What is Angie You's total ORIC stock ownership after the June 2025 purchases?

Following the reported transactions, Angie You directly owns 28,000 shares of ORIC Pharmaceuticals common stock, all held in direct ownership form (D).

What was the price range of ORIC shares purchased by Director You on June 20, 2025?

According to the filing's explanatory notes, the shares were purchased in the price range of $9.14 to $9.50, with a weighted average price of $9.3871 per share.